BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 22176478)

  • 1. Characterisation of complementary and alternative medicine use and its impact on medication adherence in inflammatory bowel disease.
    Weizman AV; Ahn E; Thanabalan R; Leung W; Croitoru K; Silverberg MS; Steinhart AH; Nguyen GC
    Aliment Pharmacol Ther; 2012 Feb; 35(3):342-9. PubMed ID: 22176478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of complementary and alternative medicine on the quality of life in inflammatory bowel disease: results from a French national survey.
    Abitbol V; Lahmek P; Buisson A; Olympie A; Poupardin C; Chaussade S; Lesgourgues B; Nahon S
    Eur J Gastroenterol Hepatol; 2014 Mar; 26(3):288-94. PubMed ID: 24407360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive factors of complementary and alternative medicine use for patients with inflammatory bowel disease in Korea.
    Park DI; Cha JM; Kim HS; Park HJ; Shin JE; Hong SN; Hong SS; Kim WJ
    Complement Ther Med; 2014 Feb; 22(1):87-93. PubMed ID: 24559822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of adherence to therapy and complementary and alternative medicine use with demographic factors and disease phenotype in patients with inflammatory bowel disease.
    Lakatos PL; Czegledi Z; David G; Kispal Z; Kiss LS; Palatka K; Kristof T; Nagy F; Salamon A; Demeter P; Miheller P; Szamosi T; Banai J; Papp M; Bene L; Kovacs A; Racz I; Lakatos L
    J Crohns Colitis; 2010 Sep; 4(3):283-90. PubMed ID: 21122517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complementary and alternative medicine use by Canadian patients with inflammatory bowel disease: results from a national survey.
    Hilsden RJ; Verhoef MJ; Best A; Pocobelli G
    Am J Gastroenterol; 2003 Jul; 98(7):1563-8. PubMed ID: 12873578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment adherence and use of complementary and alternative medicine in patients with inflammatory bowel disease].
    Lakatos L; Czeglédi Z; Dávid G; Kispál Z; Kiss LS; Palatka K; Kristóf T; Molnár T; Salamon A; Demeter P; Miheller P; Szamosi T; Banai J; Papp M; Bene L; Kovács A; Rácz I; Lakatos PL
    Orv Hetil; 2010 Feb; 151(7):250-8. PubMed ID: 20133244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of Complementary and Alternative Medicine for Inflammatory Bowel Disease Is Associated with Worse Adherence to Conventional Therapy: The COMPLIANT Study.
    Nguyen GC; Croitoru K; Silverberg MS; Steinhart AH; Weizman AV
    Inflamm Bowel Dis; 2016 Jun; 22(6):1412-7. PubMed ID: 27120570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Manitoba Inflammatory Bowel Disease Cohort Study: a prospective longitudinal evaluation of the use of complementary and alternative medicine services and products.
    Rawsthorne P; Clara I; Graff LA; Bernstein KI; Carr R; Walker JR; Ediger J; Rogala L; Miller N; Bernstein CN
    Gut; 2012 Apr; 61(4):521-7. PubMed ID: 21836028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complementary medicine use in children and young adults with inflammatory bowel disease.
    Heuschkel R; Afzal N; Wuerth A; Zurakowski D; Leichtner A; Kemper K; Tolia V; Bousvaros A
    Am J Gastroenterol; 2002 Feb; 97(2):382-8. PubMed ID: 11866277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of complementary and alternative medicine in patients with inflammatory bowel disease: results of a cross-sectional study in Norway.
    Opheim R; Bernklev T; Fagermoen MS; Cvancarova M; Moum B
    Scand J Gastroenterol; 2012 Dec; 47(12):1436-47. PubMed ID: 23003678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regional variations in the use of complementary and alternative medicines (CAM) for inflammatory bowel disease patients in Italy: an IG-IBD study.
    Bertomoro P; Renna S; Cottone M; Riegler G; Bossa F; Giglio L; Pastorelli L; Papi C; Castiglione F; Angelucci E; Pica R; Di Paolo MC; D'Incà R
    J Crohns Colitis; 2010 Sep; 4(3):291-300. PubMed ID: 21122518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patterns of complementary and alternative medicine (CAM) use in patients with inflammatory bowel disease: perceived stress is a potential indicator for CAM use.
    Langhorst J; Anthonisen IB; Steder-Neukamm U; Luedtke R; Spahn G; Michalsen A; Dobos GJ
    Complement Ther Med; 2007 Mar; 15(1):30-7. PubMed ID: 17352969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complementary and alternative medicine use and its association with medication adherence in inflammatory bowel disease and other gastrointestinal diseases.
    Almakadma AH; De Vol A; Alabdaljabar MS; Aldosari S; Muhsen I; AlFreihi O; Kurdi A; Almadi M; Alsohaibani F
    Saudi J Gastroenterol; 2023; 29(4):233-239. PubMed ID: 37282444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complementary and alternative medicine in patients with inflammatory bowel disease: A survey performed in a tertiary center in Chile.
    Fernández A; Simian D; Quera R; Flores L; Ibáñez P; Lubascher J; Figueroa C; Kronberg U; Pizarro G; Fluxá D
    Complement Ther Med; 2018 Oct; 40():77-82. PubMed ID: 30219473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complementary and alternative medicine in inflammatory bowel disease patients: frequency and risk factors.
    Fernández A; Barreiro-de Acosta M; Vallejo N; Iglesias M; Carmona A; González-Portela C; Lorenzo A; Domínguez-Muñoz JE
    Dig Liver Dis; 2012 Nov; 44(11):904-8. PubMed ID: 22795615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of complementary and alternative medicines by children and adolescents with inflammatory bowel disease.
    Day AS; Whitten KE; Bohane TD
    J Paediatr Child Health; 2004 Dec; 40(12):681-4. PubMed ID: 15569284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health-related self-perceptions over time and provider-based Complementary and Alternative Medicine (CAM) use in people with inflammatory bowel disease or arthritis.
    Sirois FM
    Complement Ther Med; 2014 Aug; 22(4):701-9. PubMed ID: 25146075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Covert dose reduction is a distinct type of medication non-adherence observed across all care settings in inflammatory bowel disease.
    Mountifield R; Andrews JM; Mikocka-Walus A; Bampton P
    J Crohns Colitis; 2014 Dec; 8(12):1723-9. PubMed ID: 25263934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Doctor communication quality and Friends' attitudes influence complementary medicine use in inflammatory bowel disease.
    Mountifield R; Andrews JM; Mikocka-Walus A; Bampton P
    World J Gastroenterol; 2015 Mar; 21(12):3663-70. PubMed ID: 25834335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complementary and alternative medicine (CAM) practices and dietary patterns in children with inflammatory bowel disease in Singapore and Malaysia.
    Ong F; Seah Lee W; Lin C; Ng RT; Yee Wong S; Lim SL; Quak SH; Aw M
    Pediatr Neonatol; 2018 Oct; 59(5):494-500. PubMed ID: 29352665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.